These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28561711)

  • 1. Optimal Management of Early and Advanced HER2 Breast Cancer.
    Hurvitz SA; Gelmon KA; Tolaney SM
    Am Soc Clin Oncol Educ Book; 2017; 37():76-92. PubMed ID: 28561711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
    Zardavas D; Fouad TM; Piccart M
    Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-positive breast cancer.
    Loibl S; Gianni L
    Lancet; 2017 Jun; 389(10087):2415-2429. PubMed ID: 27939064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease.
    Chia SK
    Am Soc Clin Oncol Educ Book; 2015; ():e41-8. PubMed ID: 25993203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
    Martin M; López-Tarruella S
    Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
    Fabi A; Malaguti P; Vari S; Cognetti F
    J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
    Blackwell K; Gligorov J; Jacobs I; Twelves C
    Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.